We are live on ! Find out more

Revolution Medicines

RVMD

Market cap $43.9B

204.97 USD

+5.11

2.56%

At close Updated Sep 25, 4:00 PM EDT

Pre-market

After hours

207.01

+2.04

1%

1 day

2.56%

5 days

6.42%

1 month

-3.03%

3 months

15.04%

6 months

117.38%

Year to date

159.39%

1 year

382.17%

5 years

588.28%

10 years

609.24%

About: Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Employees: 883

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 58.7%

Neutral 37%

Negative 4.3%

The Motley Fool

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

The Motley Fool

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?

Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company's new medicine might become the top-prescribed treatment in its indication.

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?

Baron Health Care Fund Q2 2026 Portfolio Activity

During the quarter, we added 8 new positions and exited 6 positions, bringing the number of positions in the Fund to 43. We re-established positions in two previously owned managed care companies, UnitedHealth Group Incorporated and Elevance Health, Inc. We established a new position in Sartorius Stedim Biotech S.A., which supplies equipment and reagents to biopharmaceutical companies for the production of biologic drugs.

Baron Health Care Fund Q2 2026 Portfolio Activity

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company's RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

The Motley Fool

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year. Revolution Medicines is a clinical-stage oncology specialist focused on high-stakes breakthrough therapies for RAS-addicted cancers.

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Business Insider

Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert said.

Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

Revolution Medicines Got Its Breakthrough—What Moves It Next?

Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.

Revolution Medicines Got Its Breakthrough—What Moves It Next?

Zacks Investment Research

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC).

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

See News Rankings

Price charts implemented using Lightweight Charts™